2022
Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents
Spees LP, Dinan MA, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George DJ, Scales CD, Pritchard JE, Leapman M, Gross CP, Wheeler SB. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents. Clinical Genitourinary Cancer 2022, 20: e396-e405. PMID: 35595633, PMCID: PMC9529768, DOI: 10.1016/j.clgc.2022.04.010.Peer-Reviewed Original ResearchConceptsOral anticancer agentsCause mortalityReal-world populationHazard ratioComplex patientsMetastatic renal cell carcinoma patientsFDA approvalMetastatic renal cell carcinomaRenal cell carcinoma patientsProvider-level predictorsRetrospective cohort studyCell carcinoma patientsPatients' clinical characteristicsProvider-level factorsPivotal clinical trialsState Cancer RegistryRenal cell carcinomaCox hazard modelHigh-quality careAnticancer agentsProvider Enumeration SystemMRCC patientsClinical characteristicsCohort studyPatient characteristics
2021
Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patientsProvider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaPatient-level factorsProvider-level factorsRenal cell carcinomaIndex dateRace/ethnicityInitial diagnosisCell carcinomaRisk ratioState cancer registry dataNumber of comorbiditiesMore comorbid conditionsPatient-level predictorsCancer registry dataProportion of daysProvider-level variablesPrescription drug filesMedian PDCMRCC diagnosisMRCC patientsPatient characteristicsPharmacy claimsComorbid conditionsMetastatic diagnosisMedical oncology